TapewireFind a company

person · Reporting owner

Corcoran Andrea

Disclosed activity across 1 company

Tapewire entity
60960
SEC CIK
0001296996

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Atea Pharmaceuticals, Inc.AVIR · Entity 5580See RemarksMarch 11, 2026March 13, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Atea Pharmaceuticals, Inc.

Report date March 11, 2026 · Filed March 13, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect823,576 Reported balance After 2026-03-11 transaction · row 1
1 source row

Row 1 · 2026-03-11 · Exercise / conversion · Acquired 60,000 · Balance 823,576

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.24 · Expires 2026-12-08Direct0 Reported balance After 2026-03-11 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2026-03-11 · Exercise / conversion · Acquired 60,000 · Balance 0

F1: The option is fully vested and exercisable.

Filing footnotes · ownership attribution and instrument terms

F1: The option is fully vested and exercisable.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
March 11, 2026 Filed Mar 13, 2026 18:00 UTC Atea Pharmaceuticals, Inc. AVIR · Entity 5580 Exercise / conversionStock Option (Right to Buy) · Derivative 60,000 $0.00 Strike: $1.24 $0.00
Disclosure

SEC source: 0001193125-26-106547 · ownership.xml · derivative · entry 2

Corcoran Andrea · CIK 0001296996 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 60,000 shares

Expires 2026-12-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The option is fully vested and exercisable.

Read SEC document
March 11, 2026 Filed Mar 13, 2026 18:00 UTC Atea Pharmaceuticals, Inc. AVIR · Entity 5580 Exercise / conversionCommon Stock 60,000 $1.24 $74,400.00
Disclosure

SEC source: 0001193125-26-106547 · ownership.xml · nonDerivative · entry 1

Corcoran Andrea · CIK 0001296996 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 823,576

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
January 31, 2026 Filed Feb 3, 2026 19:46 UTC Atea Pharmaceuticals, Inc. AVIR · Entity 5580 GrantStock Option (Right to Buy) · Derivative 180,000 $0.00 Strike: $4.24 $0.00
Disclosure

SEC source: 0001193125-26-036269 · ownership.xml · derivative · entry 5

Corcoran Andrea · CIK 0001296996 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 180,000

Underlying: Common Stock · 180,000 shares

Expires 2036-01-30

F5 · derivative.exercise_date: The option vests and becomes exercisable in forty-eight (48) equal monthly installments following January 31, 2026 such that the option is fully vested on January 31, 2030.

Read SEC document
January 31, 2026 Filed Feb 3, 2026 19:46 UTC Atea Pharmaceuticals, Inc. AVIR · Entity 5580 Exercise / conversionRestricted Stock Units · Derivative 10,500 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-036269 · ownership.xml · derivative · entry 4

Corcoran Andrea · CIK 0001296996 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,500 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F4 · derivative.exercise_date: Reflects RSUs following the satisfaction of performance criteria of previously granted performance restricted stock units that vested on January 31, 2026.

F4 · derivative.expiration_date: Reflects RSUs following the satisfaction of performance criteria of previously granted performance restricted stock units that vested on January 31, 2026.

Read SEC document
January 31, 2026 Filed Feb 3, 2026 19:46 UTC Atea Pharmaceuticals, Inc. AVIR · Entity 5580 Exercise / conversionRestricted Stock Units · Derivative 44,366 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-036269 · ownership.xml · derivative · entry 3

Corcoran Andrea · CIK 0001296996 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 44,366 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F3 · derivative.exercise_date: The original grant of 133,100 RSUs vested in three (3) equal annual installments on the first three anniversaries of January 31, 2023 such that the RSUs were fully vested as of January 31, 2026.

F3 · derivative.expiration_date: The original grant of 133,100 RSUs vested in three (3) equal annual installments on the first three anniversaries of January 31, 2023 such that the RSUs were fully vested as of January 31, 2026.

Read SEC document
January 31, 2026 Filed Feb 3, 2026 19:46 UTC Atea Pharmaceuticals, Inc. AVIR · Entity 5580 Tax withholdingCommon Stock 16,104 $4.24 $68,280.96
Disclosure

SEC source: 0001193125-26-036269 · ownership.xml · nonDerivative · entry 2

Corcoran Andrea · CIK 0001296996 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 763,576

Read SEC document
January 31, 2026 Filed Feb 3, 2026 19:46 UTC Atea Pharmaceuticals, Inc. AVIR · Entity 5580 Exercise / conversionCommon Stock 54,866 Not disclosed Not disclosed
Disclosure

SEC source: 0001193125-26-036269 · ownership.xml · nonDerivative · entry 1

Corcoran Andrea · CIK 0001296996 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 779,680

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F2 · balance_after: Includes 7,507 additional shares acquired under the Atea Pharmaceuticals, Inc. 2020 Employee Stock Purchase Plan.

Read SEC document
January 31, 2025 Filed Feb 4, 2025 18:00 UTC Atea Pharmaceuticals, Inc. AVIR · Entity 5580 GrantStock Option (Right to Buy) · Derivative 200,000 $0.00 Strike: $3.06 $0.00
Disclosure

SEC source: 0000950170-25-013849 · ownership.xml · derivative · entry 6

Corcoran Andrea · CIK 0001296996 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2035-01-30

F6 · derivative.exercise_date: The option vests and becomes exercisable in forty-eight (48) equal monthly installments following January 31, 2025 such that the option is fully vested on January 31, 2029.

Read SEC document
January 31, 2025 Filed Feb 4, 2025 18:00 UTC Atea Pharmaceuticals, Inc. AVIR · Entity 5580 GrantRestricted Stock Units · Derivative 10,500 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-013849 · ownership.xml · derivative · entry 5

Corcoran Andrea · CIK 0001296996 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,500

Underlying: Common Stock · 10,500 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F5 · derivative.exercise_date: Reflects RSUs following the satisfaction of performance criteria of previously granted PSUs. The RSUs will vest on January 31, 2026, subject to the Reporting Person's continued service with the Issuer.

F5 · derivative.expiration_date: Reflects RSUs following the satisfaction of performance criteria of previously granted PSUs. The RSUs will vest on January 31, 2026, subject to the Reporting Person's continued service with the Issuer.

Read SEC document
January 31, 2025 Filed Feb 4, 2025 18:00 UTC Atea Pharmaceuticals, Inc. AVIR · Entity 5580 Exercise / conversionRestricted Stock Units · Derivative 44,367 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-013849 · ownership.xml · derivative · entry 4

Corcoran Andrea · CIK 0001296996 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 44,366

Underlying: Common Stock · 44,367 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F4 · derivative.exercise_date: The original grant of 133,100 RSUs vested or will vest in three (3) equal annual installments on the first three anniversaries of January 31, 2023 such that the RSUs are fully vested on January 31, 2026.

F4 · derivative.expiration_date: The original grant of 133,100 RSUs vested or will vest in three (3) equal annual installments on the first three anniversaries of January 31, 2023 such that the RSUs are fully vested on January 31, 2026.

Read SEC document
January 31, 2025 Filed Feb 4, 2025 18:00 UTC Atea Pharmaceuticals, Inc. AVIR · Entity 5580 Tax withholdingCommon Stock 16,102 $3.06 $49,272.12
Disclosure

SEC source: 0000950170-25-013849 · ownership.xml · nonDerivative · entry 3

Corcoran Andrea · CIK 0001296996 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 717,307

Read SEC document
January 31, 2025 Filed Feb 4, 2025 18:00 UTC Atea Pharmaceuticals, Inc. AVIR · Entity 5580 GrantCommon Stock 10,500 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-25-013849 · ownership.xml · nonDerivative · entry 2

Corcoran Andrea · CIK 0001296996 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 733,409

F3 · price: Reflects shares received upon the satisfaction of performance criteria and time-vesting requirements associated with previously granted performance restricted stock units ("PSUs").

Read SEC document
January 31, 2025 Filed Feb 4, 2025 18:00 UTC Atea Pharmaceuticals, Inc. AVIR · Entity 5580 Exercise / conversionCommon Stock 44,367 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-25-013849 · ownership.xml · nonDerivative · entry 1

Corcoran Andrea · CIK 0001296996 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 722,909

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F2 · balance_after: Includes 8,334 additional shares acquired under the Atea Pharmaceuticals, Inc. 2020 Employee Stock Purchase Plan.

Read SEC document
February 01, 2024 Filed Feb 2, 2024 21:31 UTC Atea Pharmaceuticals, Inc. AVIR · Entity 5580 SaleCommon Stock 15,843 $3.84 $60,914.75
Disclosure

SEC source: 0000950170-24-010973 · ownership.xml · nonDerivative · entry 2

Corcoran Andrea · CIK 0001296996 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 670,208

F3 · shares: Shares were sold solely to cover taxes upon the vesting of restricted stock units pursuant to a standing Rule 10b5-1 instruction dated March 14, 2022.

Read SEC document
January 31, 2024 Filed Feb 2, 2024 21:31 UTC Atea Pharmaceuticals, Inc. AVIR · Entity 5580 GrantStock Option (Right to Buy) · Derivative 200,000 $0.00 Strike: $4.16 $0.00
Disclosure

SEC source: 0000950170-24-010973 · ownership.xml · derivative · entry 4

Corcoran Andrea · CIK 0001296996 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2034-01-30

F5 · derivative.exercise_date: The option vests and becomes exercisable in forty-eight (48) equal monthly installments following January 31, 2024 such that the option is fully vested on January 31, 2028.

Read SEC document
January 31, 2024 Filed Feb 2, 2024 21:31 UTC Atea Pharmaceuticals, Inc. AVIR · Entity 5580 Exercise / conversionRestricted Stock Units · Derivative 44,367 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-010973 · ownership.xml · derivative · entry 3

Corcoran Andrea · CIK 0001296996 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 88,733

Underlying: Common Stock · 44,367 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F4 · derivative.exercise_date: The original grant of 133,100 RSUs vested or will vest in three (3) equal annual installments on the first three anniversaries of January 31, 2023 such that the RSUs are fully vested on January 31, 2026.

F4 · derivative.expiration_date: The original grant of 133,100 RSUs vested or will vest in three (3) equal annual installments on the first three anniversaries of January 31, 2023 such that the RSUs are fully vested on January 31, 2026.

Read SEC document
January 31, 2024 Filed Feb 2, 2024 21:31 UTC Atea Pharmaceuticals, Inc. AVIR · Entity 5580 Exercise / conversionCommon Stock 44,367 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-010973 · ownership.xml · nonDerivative · entry 1

Corcoran Andrea · CIK 0001296996 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 686,051

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F2 · balance_after: Includes 8,680 additional shares acquired under the Atea Pharmaceuticals, Inc. 2020 Employee Stock Purchase Plan.

Read SEC document
January 31, 2023 Filed Feb 2, 2023 18:30 UTC Atea Pharmaceuticals, Inc. AVIR · Entity 5580 GrantStock Option (Right to Buy) · Derivative 186,300 $0.00 Strike: $4.63 $0.00
Disclosure

SEC source: 0000899243-23-003607 · doc4.xml · derivative · entry 2

Corcoran Andrea · CIK 0001296996 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 186,300

Underlying: Common Stock · 186,300 shares

Expires 2033-01-30

F3 · derivative.exercise_date: The option vests and becomes exercisable in forty-eight (48) equal monthly installments following January 31, 2023 such that the option is fully vested on January 31, 2027.

Read SEC document
January 31, 2023 Filed Feb 2, 2023 18:30 UTC Atea Pharmaceuticals, Inc. AVIR · Entity 5580 GrantRestricted Stock Units · Derivative 133,100 $0.00 $0.00
Disclosure

SEC source: 0000899243-23-003607 · doc4.xml · derivative · entry 1

Corcoran Andrea · CIK 0001296996 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 133,100

Underlying: Common Stock · 133,100 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F2 · derivative.exercise_date: The RSUs vest in three (3) equal annual installments on the first three anniversaries of the grant date such that the RSUs are fully vested on January 31, 2026.

F2 · derivative.expiration_date: The RSUs vest in three (3) equal annual installments on the first three anniversaries of the grant date such that the RSUs are fully vested on January 31, 2026.

Read SEC document
January 31, 2022 Filed Feb 2, 2022 17:15 UTC Atea Pharmaceuticals, Inc. AVIR · Entity 5580 GrantStock Option (Right to Buy) · Derivative 181,000 $0.00 Strike: $7.14 $0.00
Disclosure

SEC source: 0000899243-22-004184 · doc4.xml · derivative · entry 1

Corcoran Andrea · CIK 0001296996 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 181,000

Underlying: Common Stock · 181,000 shares

Expires 2032-01-30

F1 · derivative.exercise_date: The option vests and becomes exercisable in forty-eight (48) equal monthly installments following January 31, 2022.

Read SEC document
January 29, 2021 Filed Feb 1, 2021 16:52 UTC Atea Pharmaceuticals, Inc. AVIR · Entity 5580 GrantStock Option (Right to Buy) · Derivative 148,850 $0.00 Strike: $73.00 $0.00
Disclosure

SEC source: 0000899243-21-003869 · doc4.xml · derivative · entry 1

Corcoran Andrea · CIK 0001296996 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 148,850

Underlying: Common Stock · 148,850 shares

Expires 2031-01-28

F1 · derivative.exercise_date: The option vests and becomes exercisable in forty-eight (48) equal monthly installments following January 29, 2021.

Read SEC document
November 03, 2020 Filed Nov 3, 2020 20:08 UTC Atea Pharmaceuticals, Inc. AVIR · Entity 5580 ConversionSeries B Convertible Preferred Stock · Derivative 33,004 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-030330 · doc4.xml · derivative · entry 3

Corcoran Andrea · CIK 0001296996 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 33,004 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The preferred stock was convertible at any time, at the holder's election and had no expiration date. Each share of preferred stock was automatically converted into one share of common stock upon the closing of the Issuer's initial public offering of its common stock.

F1 · price: The preferred stock was convertible at any time, at the holder's election and had no expiration date. Each share of preferred stock was automatically converted into one share of common stock upon the closing of the Issuer's initial public offering of its common stock.

F1 · derivative.exercise_date: The preferred stock was convertible at any time, at the holder's election and had no expiration date. Each share of preferred stock was automatically converted into one share of common stock upon the closing of the Issuer's initial public offering of its common stock.

F1 · derivative.expiration_date: The preferred stock was convertible at any time, at the holder's election and had no expiration date. Each share of preferred stock was automatically converted into one share of common stock upon the closing of the Issuer's initial public offering of its common stock.

Read SEC document
November 03, 2020 Filed Nov 3, 2020 20:08 UTC Atea Pharmaceuticals, Inc. AVIR · Entity 5580 ConversionSeries A Convertible Preferred Stock · Derivative 100,000 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-030330 · doc4.xml · derivative · entry 2

Corcoran Andrea · CIK 0001296996 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 100,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The preferred stock was convertible at any time, at the holder's election and had no expiration date. Each share of preferred stock was automatically converted into one share of common stock upon the closing of the Issuer's initial public offering of its common stock.

F1 · price: The preferred stock was convertible at any time, at the holder's election and had no expiration date. Each share of preferred stock was automatically converted into one share of common stock upon the closing of the Issuer's initial public offering of its common stock.

F1 · derivative.exercise_date: The preferred stock was convertible at any time, at the holder's election and had no expiration date. Each share of preferred stock was automatically converted into one share of common stock upon the closing of the Issuer's initial public offering of its common stock.

F1 · derivative.expiration_date: The preferred stock was convertible at any time, at the holder's election and had no expiration date. Each share of preferred stock was automatically converted into one share of common stock upon the closing of the Issuer's initial public offering of its common stock.

Read SEC document
November 03, 2020 Filed Nov 3, 2020 20:08 UTC Atea Pharmaceuticals, Inc. AVIR · Entity 5580 ConversionCommon Stock 133,004 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-030330 · doc4.xml · nonDerivative · entry 1

Corcoran Andrea · CIK 0001296996 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 633,004

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The preferred stock was convertible at any time, at the holder's election and had no expiration date. Each share of preferred stock was automatically converted into one share of common stock upon the closing of the Issuer's initial public offering of its common stock.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.